Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership
SEC Accession No. 0000902664-26-003281
Filing Date
2026-07-30
Accepted
2026-07-30 21:30:13
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 21641
2 ANNEX A exhibit99_1.htm EX-99.1 3179
3 JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) exhibit99_3.htm EX-99.3 4090
  Complete submission text file 0000902664-26-003281.txt   30701
Mailing Address 110 GREENE STREET SUITE 800 NEW YORK NY 10012
Business Address 110 GREENE STREET SUITE 800 NEW YORK NY 10012 212-937-4975
Avoro Capital Advisors LLC (Filed by) CIK: 0001633313 (see all company filings)

EIN.: 271007403 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D

Mailing Address 1150 MARINA VILLAGE PKWY ALAMEDA CA 94501
Business Address 1150 MARINA VILLAGE PKWY ALAMEDA CA 94501 510-454-0213
Scribe Therapeutics, Inc. (Subject) CIK: 0001853921 (see all company filings)

EIN.: 822157847 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-95831 | Film No.: 261225169
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)